Innventure, LLC to provide strategic advisory services to BioFuse Medical Technologies, Inc.
MELBOURNE, FL (February 21, 2023) BioFuse Medical Technologies, Inc., an emerging surgical device company with transformative tissue sealing and welding technology, announced today that Roland Austrup will join the company’s Board of Directors as the initial appointee of Innventure, LLC.
Roland, who serves as the Chief Financial Officer for Innventure, LLC, brings a wealth of experience in capital markets and corporate strategy for disruptive technologies, as well as strong connections with investors and multinational companies. Innventure, a company that founds, funds, operates, and rapidly scales companies in strategic collaboration with multinational corporations, will provide BioFuse with valuable strategic advisory resources to accelerate the commercialization of their disruptive tissue welding platform.
“I am pleased to welcome Roland to the BioFuse board of directors,” said Dr. Joseph Stauffer, Chairman of BioFuse Medical Technologies. “Roland’s deep experience with capital markets and corporate strategy for disruptive technologies as well as his association with investors and multi-national companies makes him an ideal member to join BioFuse at this critical inflection point.”
BioFuse technology offers the promise of saving time and money, and better patient outcomes using novel tissue welding technology. By replacing traditional sutures and staples, the technology has the potential to improve patient recovery times and reduce healthcare costs.
“I am excited to join the BioFuse board of directors and help the company accelerate towards commercialization,” said Roland Austrup, initial appointee of Innventure, LLC to BioFuse’s Board of Directors. “Innventure’s systematic, quantitative approach to founding and funding new companies, in collaboration with multinational corporations, aligns well with BioFuse’s mission to bring disruptive tissue welding technology to market and improve patient outcomes.”
##
About Innventure, LLC
Innventure, LLC is a strategic venture capital firm that focuses on partnering with multinational corporations to identify and rapidly scale opportunities in emerging technologies. Innventure’s approach is designed to mitigate the risks inherent in building and scaling high-growth ventures by leveraging market data, strategic partnerships, and a team of experienced industry professionals. The firm’s portfolio includes companies in a variety of industries, including healthcare, energy, and technology. Innventure’s goal is to create $1 billion or more in new enterprise value for each of its portfolio companies.
##
About BioFuse Medical Technologies, Inc.
BioFuse Medical Technologies’ first product offering, SurgiFuse® is a new RF tissue sealing and welding technology. Using transformative technology, proven in Europe in thousands of cases, this surgical innovation replaces traditional methods of sutures, staples, and electrosurgical vessel sealing. SurgiFuse® is a platform technology that can address a broad range of clinical applications, includes a robust pipeline of products in various stages of development, solid IP protection and trade secrets.
SurgiFuse® is an advanced high-frequency electrosurgical system that incorporates a unique and proprietary way of controlling and delivering energy to and through the target tissue. In studies, SurgiFuse® tissue fusion has been shown to be stronger than mechanical closure, creates a continuous seam in the tissue, and leaves no foreign bodies behind. SurgiFuse® encompasses the proprietary use of low voltages and high currents, optimized specifically for the tissue to be fused. In addition, energy output to the tissue occurs in pulses. These computer-controlled energy pulses create optimal temperatures that unravel large molecules in the tissue and as these molecules cool, they become intertwined and create a fusion.
This technology will serve a large and growing target market of $3 billion. Market data indicates a strong and growing demand for advanced, innovative devices that facilitate evolving surgical procedural techniques and vastly improved patient outcomes. Surgeons are looking for new technology that will eliminate scars and lower leakage and infection rates.
BioFuse Medical Technologies, Inc. is privately held and interested accredited investors may learn more about investment opportunities in the Company’s 506(c) offering by visiting: biofusemedical.com.